The equity can still compound because the story is moving from science milestones to saleable products: shippable
QPUs,
on-prem systems, and cloud availability. I assume valuation compresses sharply from today's extreme level, but not to commodity hardware, because validated
sovereign deployments, recurring support, and reserved-performance revenue would make the business look like scarce strategic compute infrastructure rather than a lab project.